Technologies: preclinical imaging for drug development

详细信息    查看全文

• 作者：Paul M. Matthews¹ ; ² ; ^{paul.m.matthews@gsk.com} ; Robert Coatney³ ; Hasan Alsaid³ ; Beat Jucker⁴ ; Sharon Ashworth¹ ; Christine Parker¹ ; Kumar Changani⁵
• 刊名：Drug Discovery Today: Technologies
• 出版年：2013
• 出版时间：September, 2013
• 年：2013
• 卷：10
• 期：3
• 页码：e343-e350
• 全文大小：1383 K

文摘

Preclinical imaging with magnetic resonance imaging (MRI), computerised tomography (CT), ultrasound (US), positron emission tomography (PET) or single-photon emission computed tomography (SPECT) enable non-invasive measures of tissue structure, function or metabolism in vivo. The technologies can add value to preclinical studies by enabling dynamic pharmacological observations on the same animal and because of possibilities for relatively direct clinical translation. Potential benefits from the application of preclinical imaging should be considered routinely in drug development.